Christopher Fowler

List of Publications by Year
in descending order

331 papers	11,203 citations	30551 56 h-index	56606 87 g-index
336 all docs	336 docs citations	336 times ranked	7393 citing authors

#	Article	IF	Citations
1	The endocannabinoid system â€“ current implications for drug development. Journal of Internal Medicine, 2021, 290, 2-26.	2.7	21
2	Design, synthesis and inÂvitro and inÂvivo biological evaluation of flurbiprofen amides as new fatty acid amide hydrolase/cyclooxygenase-2 dual inhibitory potential analgesic agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 940-953.	2.5	3
3	Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. Journal of Medicinal Chemistry, 2021, 64, 123-149.	2.9	33
4	Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH). Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127513.	1.0	4
5	Effects of orthotopic implantation of rat prostate tumour cells upon components of the N-acylethanolamine and monoacylglycerol signalling systems: an mRNA study. Scientific Reports, 2020, 10, 6314.	1.6	3
6	The Basal Pharmacology of Palmitoylethanolamide. International Journal of Molecular Sciences, 2020, 21, 7942.	1.8	62
7	Relative Deficiency of Anti-Inflammatory N-Acylethanolamines Compared to Prostaglandins in Oral Lichen Planus. Biomedicines, 2020, 8, 481.	1.4	4
8	The fatty acid amide hydrolase and cyclooxygenase-inhibitory properties of novel amide derivatives of carprofen. Bioorganic Chemistry, 2020, 101, 104034.	2.0	4
9	Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 815-823.	2.5	9
10	Enhanced Analgesic Effects and Gastrointestinal Safety of a Novel, Hydrogen Sulfide-Releasing Anti-Inflammatory Drug (ATB-352): A Role for Endogenous Cannabinoids. Antioxidants and Redox Signaling, 2020, 33, 1003-1009.	2.5	25
11	Changes in Proportions of Linoleic Acid-derived Oxylipins in Oral Lichen Planus. Acta Dermato-Venereologica, 2019, 99, 1051-1052.	0.6	4
12	Altered mRNA Expression of Genes Involved in Endocannabinoid Signalling in Squamous Cell Carcinoma of the Oral Tongue. Cancer Investigation, 2019, 37, 327-338.	0.6	7
13	Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 562-576.	2.5	6
14	Role of pannexin-1 in the cellular uptake, release and hydrolysis of anandamide by T84 colon cancer cells. Scientific Reports, 2019, 9, 7622.	1.6	7
15	Low mRNA expression and activity of monoacylglycerol lipase in human SH-SY5Y neuroblastoma cells. Prostaglandins and Other Lipid Mediators, 2019, 142, 59-67.	1.0	4
16	Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a â€œTail Switchingâ€•Strategy on a Piperazinyl Azetidine Skeleton. Journal of Medicinal Chemistry, 2019, 62, 3336-3353.	2.9	28
17	What influences chronic pain management? A bestâ€“worst scaling experiment with final year medical students and general practitioners. British Journal of Pain, 2019, 13, 214-225.	0.7	6
18	Interferon Î³ treatment increases endocannabinoid and related Nâ€acylethanolamine levels in T84 human colon carcinoma cells. British Journal of Pharmacology, 2019, 176, 1470-1480.	2.7	9

#	Article	IF	Citations
19	In Vitro and in Vivo Evaluation of ¹¹C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies. Journal of Medicinal Chemistry, 2018, 61, 2278-2291.	2.9	41
20	Involvement of CYP1B1 in interferon Î³â€induced alterations of epithelial barrier integrity. British Journal of Pharmacology, 2018, 175, 877-890.	2.7	8
21	Satiety Factors Oleoylethanolamide, Stearoylethanolamide, and Palmitoylethanolamide in Motherâ€™s Milk Are Strongly Associated with Infant Weight at Four Months of Ageâ€"Data from the Odense Child Cohort. Nutrients, 2018, 10, 1747.	1.7	18
22	Differences in Swedish and Australian medical student attitudes and beliefs about chronic pain, its management, and the way it is taught. Scandinavian Journal of Pain, 2018, 18, 533-544.	0.5	4
23	Effects of culturing prostate cancer cells in acidic conditions upon the endocannabinoid signalling system. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-8-15.	0.0	0
24	N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 513-521.	2.5	5
25	Plasma levels of the endocannabinoid anandamide, related N-acylethanolamines and linoleic acid-derived oxylipins in patients with migraine. Prostaglandins Leukotrienes and Essential Fatty Acids, 2017, 120, 15-24.	1.0	22
26	Novel propanamides as fatty acid amide hydrolase inhibitors. European Journal of Medicinal Chemistry, 2017, 136, 523-542.	2.6	10
27	The anti-inflammatory compound palmitoylethanolamide inhibits prostaglandin and hydroxyeicosatetraenoic acid production by a macrophage cell line. Pharmacology Research and Perspectives, 2017, 5, e00300.	1.1	33
28	TLR4 receptor expression and function in F11 dorsal root ganglion Ã— neuroblastoma hybrid cells. Innate Immunity, 2017, 23, 687-696.	1.1	5
29	Endocannabinoid Turnover. Advances in Pharmacology, 2017, 80, 31-66.	1.2	24
30	Levels of oxylipins, endocannabinoids and related lipids in plasma before and after low-level exposure to acrolein in healthy individuals and individuals with chemical intolerance. Prostaglandins Leukotrienes and Essential Fatty Acids, 2017, 121, 60-67.	1.0	12
31	Effects of tumour necrosis factor Î± upon the metabolism of the endocannabinoid anandamide in prostate cancer cells. PLoS ONE, 2017, 12, e0185011.	1.1	7
32	Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. British Journal of Clinical Pharmacology, 2016, 82, 932-942.	1.1	111
33	Association between plasma concentrations of linoleic acid-derived oxylipins and the perceived pain scores in an exploratory study in women with chronic neck pain. BMC Musculoskeletal Disorders, 2016, 17, 103.	0.8	17
34	Endocannabinoids and related lipids in blood plasma following touch massage: a randomised, crossover study. BMC Research Notes, 2015, 8, 504.	0.6	7
35	Serum Levels of Oxylipins in Achilles Tendinopathy: An Exploratory Study. PLoS ONE, 2015, 10, e0123114.	1.1	25
36	Leptin Levels Are Negatively Correlated with 2-Arachidonoylglycerol in the Cerebrospinal Fluid of Patients with Osteoarthritis. PLoS ONE, 2015, 10, e0123132.	1.1	13

#	Article	IF	Citations
37	Delta⁹â€tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature. Clinical Pharmacology and Therapeutics, 2015, 97, 587-596.	2.3	34
38	The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugsâ€"A practical view. European Neuropsychopharmacology, 2015, 25, 749-762.	0.3	37
39	The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review. Handbook of Experimental Pharmacology, 2015, 231, 95-128.	0.9	38
40	Relative and absolute reliability of measures of linoleic acid-derived oxylipins in human plasma. Prostaglandins and Other Lipid Mediators, 2015, 121, 227-233.	1.0	4
41	Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. PLoS ONE, 2015, 10, e0139212.	1.1	11
42	Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding Mode. PLoS ONE, 2015, 10, e0142711.	1.1	12
43	Ketoconazole Inhibits the Cellular Uptake of Anandamide via Inhibition of FAAH at Pharmacologically Relevant Concentrations. PLoS ONE, 2014, 9, e87542.	1.1	9
44	Involvement of Fatty Acid Amide Hydrolase and Fatty Acid Binding Protein 5 in the Uptake of Anandamide by Cell Lines with Different Levels of Fatty Acid Amide Hydrolase Expression: A Pharmacological Study. PLoS ONE, 2014, 9, e103479.	1.1	18
45	Inhibition of Endocannabinoid Metabolism by the Metabolites of Ibuprofen and Flurbiprofen. PLoS ONE, 2014, 9, e103589.	1.1	9
46	Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: A Bayesian network analysis of data from a tissue microarray. Prostate, 2014, 74, 1107-1117.	1.2	8
47	Cannabidiol Improves Vasorelaxation in Zucker Diabetic Fatty Rats through Cyclooxygenase Activation. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 457-466.	1.3	42
48	The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. BMC Research Notes, 2014, 7, 441.	0.6	13
49	Effects of Two Different Specific Neck Exercise Interventions on Palmitoylethanolamide and Stearoylethanolamide Concentrations in the Interstitium of the Trapezius Muscle in Women with Chronic Neck Shoulder Pain. Pain Medicine, 2014, 15, 1379-1389.	0.9	5
50	Has FLAT fallen flat?. Trends in Pharmacological Sciences, 2014, 35, 51-52.	4.0	6
51	Effects of dietary glucose and fructose upon cannabinoid CB1 receptor functionality in the rat brain: A pilot study. Life Sciences, 2014, 108, 116-121.	2.0	4
52	A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis. Angewandte Chemie - International Edition, 2014, 53, 13765-13770.	7.2	91
53	ErbB2 Receptor Immunoreactivity in Prostate Cancer: Relationship to the Androgen Receptor, Disease Severity at Diagnosis and Disease Outcome. PLoS ONE, 2014, 9, e105063.	1.1	2
54	Chiral 1,3,4-Oxadiazol-2-ones as Highly Selective FAAH Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 8484-8496.	2.9	54

#	Article	IF	Citations
55	Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 172-182.	2.5	30
56	Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen. European Journal of Pharmacology, 2013, 720, 383-390.	1.7	30
57	Changes in cannabinoid CB1 receptor functionality in the female rat prefrontal cortex following a high fat diet. Life Sciences, 2013, 92, 757-762.	2.0	7
58	Transport of endocannabinoids across the plasma membrane and within the cell. FEBS Journal, 2013, 280, 1895-1904.	2.2	121
59	Radiosynthesis and Evaluation of [¹¹C-Carbonyl]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography. Journal of Medicinal Chemistry, 2013, 56, 201-209.	2.9	42
60	Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase. Bioorganic and Medicinal Chemistry, 2013, 21, 4351-4357.	1.4	29
61	Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain, 2013, 154, 1649-1658.	2.0	70
62	Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1579-1587.	1.2	7
63	Association between Cannabinoid CB1 Receptor Expression and Akt Signalling in Prostate Cancer. PLoS ONE, 2013, 8, e65798.	1.1	20
64	NSAIDs: eNdocannabinoid stimulating anti-inflammatory drugs?. Trends in Pharmacological Sciences, 2012, 33, 468-473.	4.0	31
65	Anandamide uptake explained?. Trends in Pharmacological Sciences, 2012, 33, 181-185.	4.0	71
66	Monoacylglycerol lipase â€“ a target for drug development?. British Journal of Pharmacology, 2012, 166, 1568-1585.	2.7	81
67	N-(4-Methoxy-2-nitrophenyl)hexadecanamide, a palmitoylethanolamide analogue, reduces formalin-induced nociception. Life Sciences, 2012, 91, 1288-1294.	2.0	9
68	Structureâ€“Activity Relationship of a New Series of Reversible Dual Monoacylglycerol Lipase/Fatty Acid Amide Hydrolase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 824-836.	2.9	30
69	CB1 Receptor Autoradiographic Characterization of the Individual Differences in Approach and Avoidance Motivation. PLoS ONE, 2012, 7, e42111.	1.1	8
70	Lysophosphatidylinositol Stimulates [35S]GTPÎ³S Binding in the Rat Prefrontal Cortex and Hippocampus. Neurochemical Research, 2012, 37, 1037-1042.	1.6	5
71	Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression. PLoS ONE, 2012, 7, e47994.	1.1	31
72	High Tumour Cannabinoid CB1 Receptor Immunoreactivity Negatively Impacts Disease-Specific Survival in Stage II Microsatellite Stable Colorectal Cancer. PLoS ONE, 2011, 6, e23003.	1.1	43

#	Article	IF	Citations
73	High Levels of N-Palmitoylethanolamide and N-Stearoylethanolamide in Microdialysate Samples from Myalgic Trapezius Muscle in Women. PLoS ONE, 2011, 6, e27257.	1.1	29
74	The effects of homogenization of rat liver in different buffer solutions on the yield and kinetic properties of monoamine oxidase. Journal of Pharmacy and Pharmacology, 2011, 30, 573-575.	1.2	15
75	Stimulation by noradrenaline of inositol phospholipid breakdown in the rat hippocampus: effect of the ambient potassium concentration. Journal of Pharmacy and Pharmacology, 2011, 38, 201-208.	1.2	18
76	Î±1-Adrenoceptor function in the rat hippocampus as assessed by noradrenaline-stimulated inositol phospholipid breakdown after destruction of noradrenergic neurons by neonatal 6-hydroxydopamine treatment. Journal of Pharmacy and Pharmacology, 2011, 38, 385-388.	1.2	9
77	The effect of age and thyroid hormones upon the ability of the chick heart to deaminate monoamines. Journal of Pharmacy and Pharmacology, 2011, 29, 593-597.	1.2	17
78	The deamination of n-pentylamine by monoamine oxidase and a semicarbazide-sensitive amine oxidase of rat heart. Journal of Pharmacy and Pharmacology, 2011, 35, 416-420.	1.2	16
79	The inhibition by clorgyline of 5-hydroxytryptamine deamination by the rat liver. Journal of Pharmacy and Pharmacology, 2011, 30, 304-309.	1.2	24
80	Substrate- and stereoselective inhibition of human brain monoamine oxidase by 4-dimethylamino-Î±, 2-dimethylphenethylamine (FLA 336). Journal of Pharmacy and Pharmacology, 2011, 33, 403-406.	1.2	38
81	On the substrate specificities of the two forms of monoamine oxidase. Journal of Pharmacy and Pharmacology, 2011, 36, 111-115.	1.2	106
82	Dopamine and apomorphine do not modulate the uptake of [3H]D-aspartate in the rat striatum in-vitro. Journal of Pharmacy and Pharmacology, 2011, 40, 307-308.	1.2	1
83	The effect of lipid-depletion on the kinetic properties of rat liver monoamine oxidase-B. Journal of Pharmacy and Pharmacology, 2011, 32, 681-688.	1.2	24
84	Monoamine oxidase-A selective inhibition in human hypothalamus and liver in-vitro by amiflamine and its metabolites. Journal of Pharmacy and Pharmacology, 2011, 37, 352-354.	1.2	2
85	Investigation into the effects in-vitro of the 5-hydroxytryptamine reuptake inhibitor, alaproclate, on carbachol-stimulated inositol phospholipid breakdown in the rat cerebral cortex. Journal of Pharmacy and Pharmacology, 2011, 39, 1015-1018.	1.2	4
86	Residual effects of focal brain ischaemia upon cannabinoid CB1 receptor density and functionality in female rats. Brain Research, 2011, 1373, 195-201.	1.1	3
87	The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications. Journal of Pharmacy and Pharmacology, 2011, 33, 341-347.	1.2	94
88	The effect of tris buffers on rat liver mitochondrial monoamine oxidase. Journal of Pharmacy and Pharmacology, 2011, 29, 411-415.	1.2	39
89	Increased Expression of Cannabinoid CB1 Receptors in Achilles Tendinosis. PLoS ONE, 2011, 6, e24731.	1.1	14
90	Targeting the Endocannabinoid System for the Treatment of Cancer â€“ A Practical View. Current Topics in Medicinal Chemistry, 2010, 10, 814-827.	1.0	35

#	Article	IF	Citations
91	Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. British Journal of Pharmacology, 2010, 160, 549-560.	2.7	38
92	Inhibition of monoacylglycerol lipase by troglitazone, Nâ€arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays. British Journal of Pharmacology, 2010, 161, 1512-1526.	2.7	22
93	Tumour Cannabinoid CB1 Receptor and Phosphorylated Epidermal Growth Factor Receptor Expression Are Additive Prognostic Markers for Prostate Cancer. PLoS ONE, 2010, 5, e15205.	1.1	19
94	Synthesis and Evaluation of Paracetamol Esters As Novel Fatty Acid Amide Hydrolase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 2286-2298.	2.9	24
95	Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity?. Experimental Neurology, 2010, 224, 37-47.	2.0	70
96	Fatty Acid Amide Hydrolase in Prostate Cancer: Association with Disease Severity and Outcome, CB1 Receptor Expression and Regulation by IL-4. PLoS ONE, 2010, 5, e12275.	1.1	61
97	Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Research Reviews, 2009, 60, 255-266.	9.1	180
98	Effect of nitric oxide donors on membrane tritium accumulation of endocannabinoids and related endogenous lipids. European Journal of Pharmacology, 2009, 621, 10-18.	1.7	3
99	The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 2994-3008.	2.6	28
100	The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. British Journal of Pharmacology, 2009, 156, 412-419.	2.7	61
101	A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. European Journal of Cancer, 2009, 45, 174-182.	1.3	102
102	A novel inhibitor of fatty acid amide hydrolase, the enzyme responsible for the hydrolysis of the endocannabinoid anandamide. FASEB Journal, 2009, 23, 756.15.	0.2	0
103	Pharmacological Properties of Cannabinoid Receptors in the Avian Brain: Similarity of Rat and Chicken Cannabinoid1 Receptor Recognition Sites and Expression of Cannabinoid2 Receptor-Like Immunoreactivity in the Embryonic Chick Brain. Basic and Clinical Pharmacology and Toxicology, 2008, 88, 213-222.	0.0	0
104	Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids. British Journal of Pharmacology, 2008, 155, 244-252.	2.7	47
105	Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake?. Pharmacological Research, 2008, 58, 72-76.	3.1	19
106	“The Tools of the Trade” â€“ An Overview of the Pharmacology of the Endocannabinoid System. Current Pharmaceutical Design, 2008, 14, 2254-2265.	0.9	26
107	Removal of Endocannabinoids by the Body: Mechanisms and Therapeutic Possibilities. , 2008, , 31-46.		0
108	Structureâ^'Activity Relationship of a Series of Inhibitors of Monoacylglycerol HydrolysisComparison with Effects upon Fatty Acid Amide Hydrolaseâ€. Journal of Medicinal Chemistry, 2007, 50, 5012-5023.	2.9	12

#	Article	IF	Citations
109	Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. British Journal of Pharmacology, 2007, 150, 186-191.	2.7	82
110	The â€˜specificâ€™ tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. British Journal of Pharmacology, 2007, 150, 951-960.	2.7	26
111	Interaction of ligands for the peroxisome proliferator-activated receptor Î³ with the endocannabinoid system. British Journal of Pharmacology, 2007, 151, 1343-1351.	2.7	32
112	The contribution of cyclooxygenaseâ€2 to endocannabinoid metabolism and action. British Journal of Pharmacology, 2007, 152, 594-601.	2.7	82
113	Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolaseâ€driven uptake. British Journal of Pharmacology, 2007, 152, 744-750.	2.7	44
114	Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. European Journal of Pharmacology, 2007, 565, 26-36.	1.7	61
115	The Pharmacology of the Cannabinoid Systemâ€”A Question of Efficacy and Selectivity. Molecular Neurobiology, 2007, 36, 15-25.	1.9	25
116	The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacological Research, 2006, 54, 481-485.	3.1	30
117	The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of Î²-hexosaminidase from skin slices in vitro. Life Sciences, 2006, 78, 598-606.	2.0	33
118	Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. Journal of Neurochemistry, 2006, 99, 677-688.	2.1	27
119	The cannabinoid system and its pharmacological manipulation ? a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundamental and Clinical Pharmacology, 2006, 20, 549-562.	1.0	56
120	The Endocannabinoid System: Current Pharmacological Research and Therapeutic Possibilities. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 124-134.	1.2	48
121	Is there a temperature-dependent uptake of anandamide into cells?. British Journal of Pharmacology, 2006, 149, 73-81.	2.7	21
122	A novel assay for monoacylglycerol hydrolysis suitable for high-throughput screening. Analytical Biochemistry, 2006, 359, 40-44.	1.1	9
123	The cannabinoid agonist WIN 55,212-2 inhibits TNF-Î±-induced neutrophil transmigration across ECV304 cells. European Journal of Pharmacology, 2006, 547, 165-173.	1.7	37
124	Measurement of saturable and non-saturable components of anandamide uptake into P19 embryonic carcinoma cells in the presence of fatty acid-free bovine serum albumin. Chemistry and Physics of Lipids, 2005, 134, 131-139.	1.5	26
125	Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. British Journal of Pharmacology, 2005, 145, 885-893.	2.7	42
126	Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. British Journal of Pharmacology, 2005, 146, 467-476.	2.7	148

#	Article	IF	Citations
127	Cyclooxygenation of the arachidonoyl side chain of 1-arachidonoylglycerol and related compounds block their ability to prevent anandamide and 2-oleoylglycerol metabolism by rat brain in vitro. Biochemical Pharmacology, 2005, 69, 1241-1245.	2.0	14
128	The endocannabinoid signaling system: Pharmacological and therapeutic aspects. Pharmacology Biochemistry and Behavior, 2005, 81, 248-262.	1.3	69
129	The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications. ChemInform, 2005, 36, no.	0.1	0
130	Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors. CNS and Neurological Disorders, 2005, 4, 685-696.	4.3	17
131	The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications. Journal of Medicinal Chemistry, 2005, 48, 5059-5087.	2.9	307
132	Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochemical and Biophysical Research Communications, 2005, 337, 104-109.	1.0	42
133	Oleamide: a member of the endocannabinoid family?. British Journal of Pharmacology, 2004, 141, 195-196.	2.7	42
134	Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. British Journal of Pharmacology, 2004, 143, 774-784.	2.7	79
135	Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysisâ€"a difficult issue to handle. European Journal of Pharmacology, 2004, 492, 1-11.	1.7	86
136	Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. European Journal of Pharmaceutical Sciences, 2004, 22, 181-189.	1.9	34
137	Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends in Pharmacological Sciences, 2004, 25, 59-61.	4.0	79
138	Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sciences, 2004, 76, 461-472.	2.0	3
139	A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. Journal of Proteomics, 2004, 60, 171-177.	2.4	59
140	Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, A Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, A Possible Target for the Treatment of Neurodegenerative Diseases and Pain. Current Medicinal Chemistry - Central Nervous System Agents, 2004, 4, 161-174.	0.6	12
141	Effects of water-soluble cigarette smoke extracts upon the release of ?-hexosaminidase from RBL-2H3 basophilic leukaemia cells in response to substance P, compound 48/80, concanavalin A and antigen stimulation. Inflammation Research, 2003, 52, 461-469.	1.6	18
142	AM404 and VDMÂ11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. Archives of Toxicology, 2003, 77, 201-207.	1.9	23
143	Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 237-244.	1.4	22
144	Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochemical Pharmacology, 2003, 66, 757-767.	2.0	44

#	Article	IF	Citations
145	Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. European Journal of Medicinal Chemistry, 2003, 38, 403-412.	2.6	42
146	N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Bioorganic and Medicinal Chemistry, 2003, 11, 817-825.	1.4	11
147	Esters, Retroesters, and a Retroamide of Palmitic Acid: Pool for the First Selective Inhibitors of N-Palmitoylethanolamine- Selective Acid Amidase. Journal of Medicinal Chemistry, 2003, 46, 4373-4376.	2.9	41
148	Modifications of the Ethanolamine Head in N-Palmitoylethanolamine:â€‰ Synthesis and Evaluation of New Agents Interfering with the Metabolism of Anandamide. Journal of Medicinal Chemistry, 2003, 46, 1440-1448.	2.9	40
149	Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Brain Research Reviews, 2003, 41, 26-43.	9.1	71
150	Cannabinoid CB1 receptor activation does not prevent the toxicity of glutamate towards embryonic chick telencephalon primary cultures. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2003, 136, 245-251.	1.3	4
151	Design, Synthesis, and Biological Evaluation of New Inhibitors of the Endocannabinoid Uptake:â€‰ Comparison with Effects on Fatty Acid Amidohydrolase. Journal of Medicinal Chemistry, 2003, 46, 1512-1522.	2.9	83
152	Inhibition of Fatty Acid Amidohydrolase, the Enzyme Responsible for the Metabolism of the Endocannabinoid Anandamide, by Analogues of Arachidonoyl-serotonin. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 225-231.	2.5	18
153	Acidic Nonsteroidal Anti-inflammatory Drugs Inhibit Rat Brain Fatty Acid Amide Hydrolase in a pH-dependent Manner. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 55-58.	2.5	50
154	The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents ?. Current Medicinal Chemistry, 2002, 9, 663-674.	1.2	277
155	Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamideâ€”targets for drug development?. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 193-200.	1.0	63
156	â€˜Entourageâ€™ effects of N -acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. British Journal of Pharmacology, 2002, 136, 452-458.	2.7	129
157	Human platelet calcium mobilisation in response to ÃŸ-amyloid (25â€“35): buffer dependency and unchanged response in Alzheimerâ€™s disease. Neurochemistry International, 2001, 38, 145-151.	1.9	11
158	Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced Î²-hexosaminidase, serotonin and TNFÎ± release from rat RBL-2H3 basophilic leukaemia cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 66-73.	1.4	43
159	Effects of staurosporine, U-73122, wortmannin, 4-hydroxynonenal and sodium azide upon the release of secreted beta-amyloid precursor protein from human platelets in response to thrombin stimulation. Molecular and Cellular Biochemistry, 2001, 219, 145-152.	1.4	4
160	Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. British Journal of Pharmacology, 2001, 132, 1743-1754.	2.7	47
161	Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. British Journal of Pharmacology, 2001, 133, 513-520.	2.7	36
162	Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. British Journal of Pharmacology, 2001, 133, 1263-1275.	2.7	141

#	Article	IF	Citations
163	oleamide11Abbreviations: AEA, anandamide, arachidonyl ethanolamide; PEA, palmitoylethanolamide, N-(2-hydroxyethyl) hexadecamide; FAAH, fatty acid amide hydrolase; CB, cannabinoid; PMSF, phenylmethylsulfonyl fluoride; MAFP, methyl arachidonyl fluorophosphonate; methAEA,	2.0	123
164	Pharmacological Properties of Cannabinoid Receptors in the Avian Brain: Similarity of Rat and Chicken Cannabinoid1 Receptor Recognition Sites and Expression of Cannabinoid2 Receptor-Like Immunoreactivity in the Embryonic Chick Brain. Basic and Clinical Pharmacology and Toxicology, 2001, 88, 213-222.	0.0	29
165	Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. Journal of Pharmacology and Experimental Therapeutics, 2001, 299, 951-9.	1.3	137
166	Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. British Journal of Pharmacology, 2000, 131, 498-504.	2.7	33
167	Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochemical Pharmacology, 2000, 60, 1807-1813.	2.0	81
168	Pharmacological properties of rat brain fatty acid amidohydrolase in different subcellular fractions using palmitoylethanolamide as substrate. Biochemical Pharmacology, 2000, 59, 647-653.	2.0	28
169	Neurotoxicity of glutamate in chick telencephalon neurons: reduction of toxicity by preincubation with carbachol, but not by the endogenous fatty acid amides anandamide and palmitoylethanolamide. Archives of Toxicology, 2000, 74, 161-164.	1.9	19
170	Rapid Inhibition by Sodium Azide of the Phosphoinositide-Mediated Calcium Response to Serotonin Stimulation in Human Platelets: Preservation in Alzheimer's Disease. Biochemical and Biophysical Research Communications, 2000, 274, 472-476.	1.0	4
171	Effects of sodium azide on the secretion of soluble amyloid-Î² precursor protein and the accumulation of Î²-amyloid(1â€“40) in cultured chick neurons. Neuroscience Letters, 2000, 288, 203-206.	1.0	3
172	Î²-amyloid(25-35) inhibits the activity of inositol (1,4,5)-trisphosphate-5-phosphatase. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 90-94.	1.4	1
173	Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: effects of nmda antagonists, antioxidants and mao inhibitors. Neurochemistry International, 1999, 34, 49-62.	1.9	49
174	The effect of hydrogen peroxide upon Î²-adrenoceptor density and function in C6 rat glioma cells. Neurochemistry International, 1999, 34, 63-70.	1.9	1
175	Serotonin stimulation of calcium mobilisation in human platelets: choice of units of measurement, effects of age and tobacco use, and correlation with serotonin2A receptor density. Clinica Chimica Acta, 1999, 287, 1-18.	0.5	4
176	Inhibition of Anandamide Hydrolysis by the Enantiomers of Ibuprofen, Ketorolac, and Flurbiprofen. Archives of Biochemistry and Biophysics, 1999, 362, 191-196.	1.4	71
177	Evidence for Cooperative Binding of (â^')Isoproterenol to Rat Brain Î²1-adrenergic Receptors. Biochemical and Biophysical Research Communications, 1999, 257, 629-634.	1.0	10
178	The Sulphydryl Oxidizing Reagent Diamide Affects Phosphoinositide-Mediated Signal Transduction. Cellular Signalling, 1998, 10, 399-406.	1.7	3
179	Serotonin-Stimulated Calcium Responses in Human Platelets. Cellular Signalling, 1998, 10, 561-568.	1.7	6
180	Characterization of the N-methyl-d-aspartate (NMDA) receptor in the embryonic chick brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 625-633.	1.4	8

#	Article	IF	Citations
181	Comparison of the effects of hydrogen peroxide, 4-hydroxy-2-nonenal and Î²-amyloid (25â€“35) upon calcium signalling. Neurochemistry International, 1998, 33, 161-172.	1.9	15
182	Presenilin-1 in Neuroblastoma Cells. Toxicology in Vitro, 1998, 12, 579-583.	1.1	1
183	The secretion of soluble amyloid beta precursor protein (AÎ²PPs) by chick neurons in serum-free primary culture is not regulated by protein kinase C. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 227-237.	1.4	4
184	Comparison of the Effects of a Series of Î¹-Opioid Receptor Agonists Upon Sodium Channel Function in Rat Brain Miniprisms. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1997, 117, 69-73.	0.5	0
185	Calibration of Fura-2 signals introduces errors into measurement of thrombin-stimulated calcium mobilisation in human platelets. Clinica Chimica Acta, 1997, 265, 247-261.	0.5	17
186	The role of the phosphoinositide signalling system in the pathogenesis of sporadic Alzheimer's disease: a hypothesis. Brain Research Reviews, 1997, 25, 373-380.	9.1	19
187	Intracellular Inositol(1,4,5)-Trisphosphate Receptor Levels Are Preserved in Alzheimerâ€™s Disease Platelets. Neurobiology of Aging, 1997, 18, 559-561.	1.5	4
188	Alzheimerâ€™s, Ageing and Amyloid: An Absurd Allegory?. Gerontology, 1997, 43, 132-142.	1.4	16
189	Ibuprofen Inhibits the Metabolism of the Endogenous Cannabimimetic Agent Anandamide. Basic and Clinical Pharmacology and Toxicology, 1997, 80, 103-107.	0.0	45
190	Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. Journal of Pharmacology and Experimental Therapeutics, 1997, 283, 729-34.	1.3	65
191	Receptor-Effector Coupling Dysfunctions in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1996, 786, 294-304.	1.8	28
192	Neurotransmitter Receptor/G-protein Mediated Signal Transduction in Alzheimer's Disease Brain. Experimental Neurology, 1996, 5, 483-488.	1.7	17
193	Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Acta Neurologica Scandinavica, 1996, 94, 25-32.	1.0	24
194	Mechanisms of Local Anesthetic Action. Anesthesia and Analgesia, 1996, 82, 673-674.	1.1	0
195	Mechanisms of Local Anesthetic Action. Anesthesia and Analgesia, 1996, 82, 673-674.	1.1	1
196	Veratrine-Stimulated Phosphoinositide Breakdown as an Assay for Local Anesthetic Actions at Na+ Channels. Anesthesia and Analgesia, 1995, 81, 480-485.	1.1	3
197	Veratrine-Stimulated Phosphoinositide Breakdown as an Assay for Local Anesthetic Actions at Na+ Channels. Anesthesia and Analgesia, 1995, 81, 480-485.	1.1	5
198	Characteristics of [3H]inositol(1,3,4,5)tetrakisphosphate recognition sites in human cerebellar membranes. Journal of Neural Transmission, 1995, 100, 101-109.	1.4	1

#	Article	IF	Citations
199	Disturbances in signal transduction mechanisms in Alzheimer's disease. Molecular and Cellular Biochemistry, 1995, 149-150, 287-292.	1.4	25
200	Pharmacological characterization of the N-methyl-d-aspartate (NMDA) receptor recognition site in porcine cerebral cortical membranes using [3H]-CGP 39653. Comparative Biochemistry and Physiology A, Comparative Physiology, 1995, 111, 39-46.	0.7	6
201	Diminished [3H]inositol(1,4,5)P3 but not [3H]inositol(1,3,4,5)P4 binding in Alzheimer's disease brain. Brain Research, 1995, 681, 160-166.	1.1	39
202	Membrane alterations in Alzheimer's disease and aging. Trends in Neurosciences, 1995, 18, 483-484.	4.2	7
203	Î¹-Opioid receptor recognition sites are not modulated by local anaesthetics. Biochemical Pharmacology, 1995, 49, 883-891.	2.0	3
204	Preservation of Î¹1 opioid receptor recognition site density and regulation by G-proteins in the temporal cortex of patients with Alzheimer's disease. Neuroscience Letters, 1995, 185, 131-134.	1.0	13
205	Disturbances in signal transduction mechanisms in Alzheimerâ€™s disease. , 1995, , 287-292.		11
206	Palladium-catalyzed synthesis of C3-substituted 3-deoxymorphines.. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 2527-2532.	1.0	14
207	Î¼-, Î´-, Î¹-Opioid receptors and their subtypes. A critical review with emphasis on radioligand binding experiments. Neurochemistry International, 1994, 24, 401-426.	1.9	100
208	Regionally selective alterations in G protein subunit levels in the Alzheimer's disease brain. Brain Research, 1994, 636, 193-201.	1.1	57
209	Characterization of [3H]CGS 19755 binding sites in the rat spinal cordâ˜†. Neurochemistry International, 1994, 24, 329-337.	1.9	7
210	Characterization of [3H]inositol 1,4,5-trisphosphate binding sites in human temporal cortical and cerebellar membranes. Neurochemistry International, 1994, 24, 73-80.	1.9	8
211	Selective loss of inositol(1,4,5)trisphosphate (IP3) but not inositol(1,3,4,5)tetrakiphosphate (IP4) receptor sites in the Alzheimer's disease brain. Neurobiology of Aging, 1994, 15, S126.	1.5	1
212	G-protein coupled signal transduction systems in the Alzheimer's disease brain. Biochemical Society Transactions, 1994, 22, 167-171.	1.6	7
213	Substance P enhances forskolin-stimulated cyclic AMP production in human UC11MG astrocytoma cells. Methods and Findings in Experimental and Clinical Pharmacology, 1994, 16, 21-8.	0.8	12
214	Local anaesthetics do not affect protein kinase C function in intact neuroblastoma cells. Life Sciences, 1993, 53, 1557-1565.	2.0	14
215	Disrupted Î²1-adrenoceptorâ€”G protein coupling in the temporal cortex of patients with Alzheimer's disease. Neuroscience Letters, 1993, 155, 163-166.	1.0	34
216	Inhibition of inositol 1,4,5-trisphosphate 5-phosphatase by micromolar concentrations of disulfiram and its analogues. Biochemical Journal, 1993, 289, 853-859.	1.7	11

#	Article	IF	Citations
217	"Specific" binding of [3H]-[Sar9,Met(O2)11]-substance P to tissue culture plates is found when substance P is used to define non-specific binding. Methods and Findings in Experimental and Clinical Pharmacology, 1993, 15, 337-43.	0.8	1
218	GH₄ZD10 cells expressing rat 5â€HT_{1A} receptors coupled to adenylyl cyclase are a model for the postsynaptic receptors in the rat hippocampus. British Journal of Pharmacology, 1992, 107, 141-145.	2.7	17
219	Preservation of Gi-protein inhibited adenylyl cyclase activity in the brains of patients with Alzheimer's disease. Neuroscience Letters, 1992, 141, 16-20.	1.0	43
220	Adenylyl Cyclase Activity in Postmortem Human Brain: Evidence of Altered G Protein Mediation in Alzheimer's Disease. Journal of Neurochemistry, 1992, 58, 1409-1419.	2.1	98
221	Brain signal transduction disturbances in neurodegenerative disorders. Cellular Signalling, 1992, 4, 1-9.	1.7	31
222	Time-dependent inhibition of inositol-1,4,5-trisphosphate-5-phosphatase by calmidazolium chloride in rat GH3 cells. Cellular Signalling, 1992, 4, 723-725.	1.7	1
223	Neurotransmitter-mediated inhibition of post-mortem human brain adenylyl cyclase. Journal of Neural Transmission, 1992, 87, 113-124.	1.4	34
224	Neurotransmitter, receptor and signal transduction disturbances in Alzheimer's disease. Acta Neurologica Scandinavica, 1992, 85, 59-62.	1.0	13
225	Is Alzheimerâ€™s Dementia a Treatable Disease?. , 1992, , 336-344.		0
226	Antagonism by 8-hydroxy-2 (DI-N-propylamino) tetraline and other serotonin agonists of muscarinic M1-type receptors coupled to inositol phospholipid breakdown in human IMR-32 and SK-N-MC neuroblastoma cells. Life Sciences, 1991, 48, 959-967.	2.0	13
227	Modulation of carbachol-stimulated inositol phospholipid breakdown in rat cerebral cortical miniprisms by excitatory amino acids and by bay K-8644 is dependent upon the assay calcium and potassium concentrations used. Life Sciences, 1991, 48, 1283-1291.	2.0	1
228	Modulation of receptor-mediated inositol phospholipid breakdown in the brain. Neurochemistry International, 1991, 19, 171-206.	1.9	39
229	Characterization and regional distribution of adenylyl cyclase activity from human brain. Neurochemistry International, 1991, 18, 389-398.	1.9	13
230	Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease. Neuroscience Letters, 1991, 133, 15-19.	1.0	39
231	Assay of a phosphatidylinositol bisphosphate phospholipase C activity in postmortem human brain. Brain Research, 1991, 543, 307-314.	1.1	25
232	Coupling of human brain cerebral cortical Î±2-adrenoceptors to GTP-binding proteins in Alzheimer's disease. Brain Research, 1991, 563, 39-43.	1.1	25
233	Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain. Journal of the Neurological Sciences, 1991, 105, 225-233.	0.3	56
234	The Na+, K+-ATPase inhibitor ouabain and the Na+ ionophore monensin have opposite effects upon carbachol-stimulated inositol phospholipid breakdown in rat cerebral cortical miniprisms. Cellular Signalling, 1991, 3, 209-213.	1.7	2

#	Article	IF	Citations
235	Somatostatin receptors and the modulation of adenylyl cyclase activity in Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 748-749.	0.9	19
236	Kinetic and inhibitor profiles of soluble and particulate inositol 1,4â€“5-trisphosphate 5-phosphatase from GH3 and IMR-32 cells. Biochemical Journal, 1990, 271, 735-742.	1.7	6
237	Reduction in ?-Adrenoceptor Density in Cultured Rat Glioma C6 Cells After Incubation with Antidepressants Is Dependent upon the Culturing Conditions Used. Journal of Neurochemistry, 1990, 55, 245-250.	2.1	16
238	Effect of monovalent ions upon G proteins coupling muscarinic receptors to phosphoinositide hydrolysis in the rat cerebral cortex. European Journal of Pharmacology, 1990, 188, 51-62.	2.7	14
239	Differential enhancement by potassium ions of M1-type and M2-type muscarinic receptor-mediated phosphoinositide breakdown in the rat brain. Neuroscience Letters, 1990, 115, 243-247.	1.0	2
240	Alzheimer's disease: is there a problem beyond recognition?. Trends in Pharmacological Sciences, 1990, 11, 183-184.	4.0	43
241	Multiple actions of fluoride ions upon the phosphoinositide cycle in the rat brain. Brain Research, 1990, 537, 93-101.	1.1	12
242	Neurotransmitter Function in Post-Mortem Human Brain: An Overview. , 1990, , 668-674.		2
243	Postmortem- and cryostability of the potassium-evoked release of [3H]5-hydroxytryptamine from rat cerebral cortical miniprisms. Journal of Neural Transmission, 1989, 75, 135-148.	1.4	4
244	Î±1-Adrenergic receptor binding sites in post-mortal human cerebral microvessel preparations: preservation in multi-infarct dementia and dementia of Alzheimer typereceptor binding sites in post-mortal human cerebral microvessel preparations: preservation in multi-infarct dementia and dementia of Alzheimer type. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1989, 1, 303-310.	1.2	9
245	Comparison of Intraâ€and Extrasynaptosomal Monoamine Oxidaseâ€A and â€B Activities in the Striatum and Frontal Cortex of Two Mice Strains with Different Sensitivities to the Neurotoxic Actions of 1â€Methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine. Basic and Clinical Pharmacology and Toxicology, 1989, 64, 276-281.	0.0	18
246	Comparison of the Effects of the Novel Antipsychotic Agent Remoxipride on Dopamine and Noradrenaline Turnover in the Rat Brain. Basic and Clinical Pharmacology and Toxicology, 1989, 65, 295-298.	0.0	2
247	Stimulation of inositol phospholipid breakdown in pig brain miniprisms by carbachol and monoamines: Effect of K+. International Journal of Biochemistry & Cell Biology, 1989, 21, 157-164.	0.8	5
248	Enhancement by Potassium of Carbachol-Stimulated Inositol Phospholipid Breakdown in Rat Cerebral Cortical Miniprisms: Comparison with Other Depolarising Agents. Journal of Neurochemistry, 1989, 52, 1843-1853.	2.1	25
249	Muscarinic receptors coupled to inositol phospholipid breakdown in human SH-SY5Y neuroblastoma cells: Effect of retinoic acid-induced differentiation. Neurochemistry International, 1989, 15, 73-79.	1.9	15
250	Selective Localization and Selective Inhibition of Monoamine Oxidase in Human Brain. , 1989, , 153-155.		0
251	Increased Duration of Dopamine Receptor Antagonistâ€Induced Effects on both Behaviour and Striatal Dopamine Turnover by Repeated Testing in Rats. Basic and Clinical Pharmacology and Toxicology, 1988, 63, 114-117.	0.0	5
252	Adrenergic, serotoninergic, histaminergic, and imipramine binding sites in post-mortal human cerebral microvessel preparations. Journal of Neural Transmission, 1988, 73, 177-189.	1.4	18

#	Article	IF	Citations
253	Norepinephrine-stimulated inositol phospholipid breakdown in the rat cerebral cortex following serotoninergic lesion. Journal of Neural Transmission, 1988, 73, 205-215.	1.4	2
254	Comparison of the effects of haloperidol, remoxipride and raclopride on ?pre?- and postsynaptic dopamine receptors in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 337, 379-84.	1.4	21
255	Validity of human brain autopsy samples for characterizing neurotransmitter function. Trends in Pharmacological Sciences, 1988, 9, 232-234.	4.0	2
256	Influence of age on effects induced by intermittent ethanol treatment on the ethanol drinking pattern and related neurochemical changes in the rat. Drug and Alcohol Dependence, 1988, 22, 117-128.	1.6	6
257	Localization and Inhibition of Monoamine Oxidase. , 1988, , 309-320.		2
258	Dopamine turnover and glutamate decarboxylase activity in the rat brain after acute and chronic treatment with raclopride, a dopamine D2-selective antagonist. Neuropharmacology, 1987, 26, 339-345.	2.0	10
259	â€˜Selectiveâ€™ lesions of brain neurotransmitters can be misleading. Trends in Pharmacological Sciences, 1987, 8, 45-46.	4.0	2
260	The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease. Neurochemistry International, 1987, 11, 359-373.	1.9	77
261	Suppression of exploratory locomotor activity and increase in dopamine turnover following the local application of cis-flupenthixol into limbic projection areas of the rat striatum. Brain Research, 1987, 402, 131-138.	1.1	73
262	Impaired performance of rats in the Morris swim-maize test late in abstinence following long-term sodium barbital treatment. Drug and Alcohol Dependence, 1987, 20, 203-212.	1.6	13
263	Comparison of the effects of dopamine D 1 and D 2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation. Journal of Neural Transmission, 1987, 69, 163-177.	1.4	31
264	Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response. Pharmacology Biochemistry and Behavior, 1987, 27, 159-164.	1.3	48
265	Antagonist Effects of the Enantiomers of 3â€PPP towards Î±‹sub›1‹/sub›â€Adrenoceptors Coupled to Inositol Phospholipid Breakdown in the Rat Cerebral Cortex. Basic and Clinical Pharmacology and Toxicology, 1987, 60, 389-392.	0.0	3
266	Stimulation of Inositol Phospholipid Breakdown in Rat Cortical and Hippocampal Miniprisms by Noradrenaline, 5â€Hydroxytryptamine and Carbachol: Some Methodological Aspects. Basic and Clinical Pharmacology and Toxicology, 1987, 60, 274-279.	0.0	52
267	The effect of selective noradrenergic lesions upon the stimulation by noradrenaline of inositol phospholipid breakdown in rat hippocampal miniprisms. European Journal of Pharmacology, 1986, 123, 401-407.	1.7	14
268	Critique of antemortem markers of Alzheimer's disease. Neurobiology of Aging, 1986, 7, 388-389.	1.5	5
269	The pros and cons of using human brain autopsy samples for radioligand binding experiments. Trends in Pharmacological Sciences, 1986, 7, 9-10.	4.0	5
270	The measurement and pharmacological characterization of neurotransmitter function in human autopsy and biopsy samples: the state of the art. Trends in Pharmacological Sciences, 1986, 7, 85-87.	4.0	4

#	Article	IF	Citations
271	Dopamine D2 receptors and dopamine metabolismRelationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology, 1986, 25, 187-197.	2.0	64
272	Seasonal variations in the stability of monoamines and their metabolites in perchloric acid as measured by high-performance liquid chromatography. Journal of Chromatography A, 1986, 361, 291-299.	1.8	26
273	Raising the ambient potassium ion concentration enhances carbachol stimulated phosphoinositide hydrolysis in rat brain hippocampal and cerebral cortical miniprisms. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 334, 10-16.	1.4	52
274	The effect of the dopamine agonist pergolide on tyrosine hydroxylase activity in rat striatal and limbic miniprisms in vitro: A model for the dopamine autoreceptor?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 333, 349-353.	1.4	3
275	Noradrenaline-stimulated inositol phospholipid breakdown as a measure of alpha1-adrenoceptor function in rat hippocampal miniprisms after repeated antidepressant treatment. Journal of Neural Transmission, 1986, 66, 197-208.	1.4	14
276	Cortical Î²â€•and Î±₂â€•Adrenoceptor Binding, Hypothalamic Noradrenaline and Pineal Melatonin Concentrations Measured at Different Times of the Day after Repeated Treatment of Rats with Imipramine, Zimeldine, Alaproclate and Amiflamine. Acta Pharmacologica Et Toxicologica, 1986, 58, 16-24.	0.0	6
277	Biochemische Aspekte der Depression im Alter - Untersuchungen an postmortalem Gewebe und zukÃ¼nftige Forschungsstrategien. , 1986, , 65-77.		0
278	"Specific" Binding of [3H]Imipramine to Protease-Sensitive and Protease-Resistant Sites. Journal of Neurochemistry, 1985, 44, 705-711.	2.1	88
279	Is inhibitio of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1985, 331, 12-19.	1.4	21
280	Increased total activity in the rat after Lâ€tryptophan plus the monoamine oxidaseâ€A inhibitor amiflamine but not after Lâ€tryptophan plus clorgyline. British Journal of Pharmacology, 1985, 85, 581-590.	2.7	8
281	Towards an animal model for the cholinergic lesion in Alzheimer's disease. Trends in Pharmacological Sciences, 1985, 6, 61.	4.0	6
282	Involvement of catechol-O-methyl transferase in the metabolism of the putative dopamine autoreceptor agonist 3-PPP(3-(3-hydroxyphenyl)-N-n-propylpiperidine). Biochemical Pharmacology, 1985, 34, 3599-3601.	2.0	6
283	Intra- and Extraneuronal Monoamine Oxidase. Journal of Vascular Research, 1984, 21, 126-131.	0.6	4
284	Inhibition of monoamine oxidase and semicarbazide-sensitive amine oxidase by mexiletine and related compounds. Naunyn-Schmiedeberg's Archives of Pharmacology, 1984, 327, 273-278.	1.4	10
285	Stereoselective inhibition of monoamine oxidase and semicarbazide-sensitive amine oxidase by 4-dimethylamino-2,?-dimethylphenethylamine (FLA 336). Naunyn-Schmiedeberg's Archives of Pharmacology, 1984, 327, 279-284.	1.4	10
286	Selective inhibitors of monoamine oxidase A and B: Biochemical, pharmacological, and clinical properties. Medicinal Research Reviews, 1984, 4, 323-358.	5.0	161
287	The formation of the acidic and alcoholic metabolites of MD 780236. Biochemical Pharmacology, 1984, 33, 1377-1378.	2.0	3
288	Brain injury and early catecholamine mobilization. Trends in Pharmacological Sciences, 1984, 5, 86.	4.0	1

#	Article	IF	Citations
289	The Metabolism of Dopamine by Both Forms of Monoamine Oxidase in the Rat Brain and Its Inhibition by Cimoxatone. Journal of Neurochemistry, 1983, 40, 1534-1541.	2.1	91
290	Cimoxatone Is a Reversible Tight-Binding Inhibitor of the A Form of Rat Brain Monoamine Oxidase. Journal of Neurochemistry, 1983, 40, 510-513.	2.1	32
291	Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition data. European Journal of Drug Metabolism and Pharmacokinetics, 1983, 8, 389-393.	0.6	1
292	The deamination of dopamine by human brain monoamine oxidase. Naunyn-Schmiedeberg's Archives of Pharmacology, 1983, 322, 198-202.	1.4	211
293	The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222. Naunyn-Schmiedeberg's Archives of Pharmacology, 1983, 323, 315-320.	1.4	38
294	The activity of monoamine oxidase -A and -B in brains from chronic alcoholics. Journal of Neural Transmission, 1983, 56, 73-83.	1.4	50
295	Concentrations of 5â€Hydroxyindoleacetic Acid and Homovanillic Acid in the Cerebrospinal Fluid of Chronic Therapyâ€Resistant Schizophrenics Before and After Hemodialysis Therapy. Artificial Organs, 1983, 7, 344-348.	1.0	2
296	Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochemical Pharmacology, 1983, 32, 47-52.	2.0	55
297	The enzyme-activated irreversible inhibition of type-B monoamine oxidase by 3-{4-[(3-chlorophenyl)methoxy]phenyl}-5-[(methylamino) methyl]-2-oxazolidinone methanesulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions. Biochemical Journal, 1983, 209, 235-242.	1.7	46
298	Factors Involved in the Selective Inhibition of Monoamine Oxidase1. Modern Problems of Pharmacopsychiatry, 1983, 19, 15-30.	2.5	11
299	Monoamine Oxidase Activity and Localisation in the Brain and the Activity in Relation to Psychiatric Disorders1. Modern Problems of Pharmacopsychiatry, 1983, 19, 246-254.	2.5	46
300	METABOLISM OF MONOAMINES IN MALIGNANT HYPERTHERMIA-SUSCEPTIBLE PIGS. British Journal of Anaesthesia, 1982, 54, 1313-1318.	1.5	4
301	Human platelet monoamine oxidaseâ€"A useful enzyme in the study of psychiatric disorders?. Neuroscience, 1982, 7, 1577-1594.	1.1	135
302	Monoamine oxidase and Le Chatelier's principle. Trends in Pharmacological Sciences, 1982, 3, 188.	4.0	0
303	Some properties of monoamine oxidase and a semicarbazide sensitive amine oxidase capable of the deamination of 5-hydroxytryptamine from porcine dental pulp. Biochemical Pharmacology, 1982, 31, 2739-2744.	2.0	24
304	Time-dependent inhibition of monoamine oxidase by Î²-phenethylamine. Biochemical Pharmacology, 1982, 31, 959-964.	2.0	30
305	The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochemical Pharmacology, 1982, 31, 3555-3561.	2.0	117
306	The binding of [3H]-5-hydroxytryptamine to homogenates of human brain. Journal of Neural Transmission, 1982, 54, 91-103.	1.4	5

#	Article	IF	Citations
307	Deamination of 5-Hydroxytryptamine by Both Forms of Monoamine Oxidase in the Rat Brain. Journal of Neurochemistry, 1982, 38, 733-736.	2.1	132
308	Monoamine oxidase activity and kinetic properties in platelet-rich plasma from controls, chronic alcoholics, and patients with nonalcoholic liver disease. Biochemical Medicine, 1981, 25, 356-365.	0.5	28
309	Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochemical Pharmacology, 1981, 30, 3329-3332.	2.0	140
310	The deamination of monoamines by pig dental pulp. Biochemical Pharmacology, 1981, 30, 403-409.	2.0	26
311	Monoamine oxidase activity in ox, elk and reindeer brains. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1981, 68, 145-149.	0.2	3
312	Low platelet monoamine oxidase activity in cigarette smokers. Life Sciences, 1981, 29, 2511-2518.	2.0	121
313	Monoamine oxidase-A and -B activities in the brain stem of schizophrenics and non-schizophrenic psychotics. Journal of Neural Transmission, 1981, 52, 23-32.	1.4	21
314	The activities of monoamine oxidase-A and-B, succinate dehydrogenase and acid phosphatase in the rat brain after hemitransection. Naunyn-Schmiedeberg's Archives of Pharmacology, 1981, 316, 51-55.	1.4	25
315	Platelet monoamine oxidase activity in Down's syndrome. Clinical Genetics, 1981, 19, 307-311.	1.0	13
316	The effect of age on the activity and molecular properties of human brain monoamine oxidase. Journal of Neural Transmission, 1980, 49, 1-20.	1.4	334
317	Titration of human brain type-B monoamine oxidase. Neurochemical Research, 1980, 5, 697-708.	1.6	19
318	Titration of human brain monoamine oxidase-A and-B by clorgyline andl-deprenil. Naunyn-Schmiedeberg's Archives of Pharmacology, 1980, 311, 263-272.	1.4	100
319	Molecular characteristics of human platelet monoamine oxidase. Naunyn-Schmiedeberg's Archives of Pharmacology, 1980, 313, 77-84.	1.4	16
320	Monoamine oxidase -A and -B activity in the rat brain after hemitransection. Life Sciences, 1980, 26, 139-146.	2.0	57
321	Platelet monoamine oxidase activity in sensation seekers. Psychiatry Research, 1980, 3, 273-279.	1.7	106
322	The nature of the substrate-selective interaction between rat liver mitochondrial monoamine oxidase and oxygen. Biochemical Pharmacology, 1980, 29, 2225-2233.	2.0	61
323	The effect of lipophilic compounds upon the activity of rat liver mitochondrial monoamine oxidase-A and -B. Biochemical Pharmacology, 1980, 29, 1177-1183.	2.0	60
324	The effect of sonication upon monoamine oxidase-A and -B in the rat liver. Biochemical Pharmacology, 1980, 29, 1185-1188.	2.0	13

#	Article	IF	Citations
325	Human platelet MAO-B - one single enzyme form?. , 1980, , 65-72.		0
326	The interaction between human platelet monoamine oxidase, its monoamine substrates and oxygen. Biochemical Pharmacology, 1979, 28, 3063-3068.	2.0	107
327	The inhibition or rat heart type A monoamine oxidase by clorgyline as a method for the estimation of enzyme active centers. Molecular Pharmacology, 1979, 16, 546-55.	1.0	21
328	The inhibition of rat brain monoamine oxidase-B by J-508 (N-methyl-N-propargyl-(1-indanyl)-ammonium) Tj ETQq0 0 0 rgBT /Overlock 10	0.4	5
329	Substrate-selective activation of rat liver mitochondrial mono amine oxidase by oxygen. Biochemical Pharmacology, 1978, 27, 1995-2000.	2.0	53
330	Monoamine oxidase A and B: A useful concept?. Biochemical Pharmacology, 1978, 27, 97-101.	2.0	246
331	The Effect of Age on the Number of Monoamine Oxidase Active Centres in the Rat Heart. Biochemical Society Transactions, 1978, 6, 955-956.	1.6	5